- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenosquamous Carcinoma, Pancreatic Cancer, Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- daraxonrasib, gemcitabine, nab-paclitaxel
- Drug
- Lead sponsor
- Revolution Medicines, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more
Location Directory
Clinical trials in Detroit, Michigan
This page shows live ClinicalTrials.gov search results for Detroit, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1670
Shown on this page
12
Current sort
Recently updated
Location scope
Detroit, MI
Filters apply within this location only.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Showing 697–708 of 1,670 matching trials in Detroit, MI.
Indexed local directory records.
Stored official records
Open in full search- Conditions
- Pulmonary Artery Stenosis
- Interventions
- PALMAZ MULLINS XD™ Pulmonary Stent
- Device
- Lead sponsor
- Cordis US Corp.
- Industry
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 8
- States / cities
- Sacramento, California • Atlanta, Georgia • Detroit, Michigan + 5 more
- Conditions
- Bronchiectasis With Pseudomonas Aeruginosa Colonization
- Interventions
- AZD0292, Placebo
- Biological · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 25
- States / cities
- Orange, California • San Francisco, California • Denver, Colorado + 22 more
- Conditions
- High Risk Newly Diagnosed Multiple Myeloma
- Interventions
- Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant
- Drug
- Lead sponsor
- Multiple Myeloma Research Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 12
- States / cities
- Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
- Interventions
- Biospecimen Collection, Echocardiography, Magnetic Resonance Imaging, Mammography, Multigated Acquisition Scan, Pertuzumab, Questionnaire Administration, Trastuzumab (Herceptin), Ultrasound
- Procedure · Biological · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,524 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 698
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 537 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Belzutifan, HC-7366
- Drug
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Essential Thrombocythemia
- Interventions
- Anagrelide, Bomedemstat, Busulfan, Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b, Ruxolitinib
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Glendale, Arizona • Glendale, California • Stanford, California + 12 more
- Conditions
- Hypertension, Hypertension, Essential, Hypertension, Systolic
- Interventions
- Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated
- Device
- Lead sponsor
- Orchestra BioMed, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 72
- States / cities
- Scottsdale, Arizona • Glendale, California • Newport Beach, California + 60 more
- Conditions
- Pulmonary Sarcoidosis
- Interventions
- XTMAB-16 or Placebo
- Drug
- Lead sponsor
- Xentria, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Denver, Colorado • Jacksonville, Florida + 12 more
- Conditions
- Colorectal Adenoma, Colorectal Cancer, Colorectal Neoplasms, Colorectal Polyp, Digestive System Disease
- Interventions
- Colonoscopy, FIT
- Diagnostic Test
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 65 Years to 82 Years
- Enrollment
- 6,434 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2035
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • San Diego, California + 17 more
- Conditions
- Advanced Malignant Neoplasm, Advanced Solid Tumor, Breast Cancer, Colorectal Cancer, ER/PR Positive Breast Cancer, ER/PR(+), Her2(-) Breast Cancer, Endometrial Cancer, Gall Bladder Cancer, HER2+ Breast Cancer, HER2- Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Head and Neck Cancer, Locally Advanced, Lung Cancer, Metastatic Cancer, Metastatic Solid Tumor, NSCLC, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Other Cancer, Ovarian Cancer, Prostate Cancer, SCLC, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, TNBC, Triple Negative Breast Cancer
- Interventions
- pembrolizumab, rezatapopt
- Drug
- Lead sponsor
- PMV Pharmaceuticals, Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Irvine, California • La Jolla, California • Los Angeles, California + 26 more
- Conditions
- Grade 2 Meningioma, Intracranial Meningioma
- Interventions
- Biospecimen Collection, Clinical Observation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment
- Procedure · Other · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 198
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 162 more